Table 3.

Secondary protective immunity to LVS can be reconstituted in BKO mice with LVS primed B cellsa

Mouse groupLVS i.d. dose (day 0)Transfer, i.v. (day 28)Ab titer (day 34)LVS, i.p. (day 35)No. of deaths/total
Expt 1
 C57BL/6JPBS<1:105 × 105 5/5
105 1:8005 × 105 0/5
 C57.Igh6 105 PBS<1:105 × 105 5/5
105 IMS<1:105 × 105 5/5
105 2 × 107 (primed B cells)<1:105 × 105 2/5
Expt 2
 C57BL/6JPBS<1:105 × 105 5/5
105 1:12805 × 105 0/4
 C57.Igh6 105 PBS<1:105 × 105 5/5
105 3 × 107 (primed B cells)<1:105 × 105 1/5
105 3 × 107 (unprimed B cells)<1:105 × 105 4/5
  • a The indicated mice (groups of four or five) were primed with 105 LVS i.d. on day 0, given either PBS or the indicated number of normal C57BL/6J or LVS-primed spleen cells i.v. on day 28, bled for serum on day 34, and challenged with 5 × 105 LVS i.p. on day 35. Actual priming and challenge doses were confirmed by plate count at the time of inoculation. Mice were observed for morbidity and mortality through day 30, at which time surviving mice were sacrificed to assess the clearance of bacteria from the spleens, livers, and lungs. These experiments are representative of three total experiments of similar design. Ab, antibody.